{
    "clinical_study": {
        "@rank": "126247", 
        "acronym": "paradigm\u21226", 
        "arm_group": {
            "arm_group_label": "50 EDs (exposure days)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial is conducted globally. The aim of the trial is to investigate the safety and\n      efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B."
        }, 
        "brief_title": "Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B", 
        "completion_date": {
            "#text": "October 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Congenital Bleeding Disorder", 
            "Haemophilia B"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemophilia B", 
                "Hemophilia A", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any trial-related activities. Trial-related\n             activities are any procedures that are carried out as part of the trial, including\n             activities to determine suitability for the trial\n\n          -  Male, age below 6 years at the time of signing informed consent\n\n          -  Patients with the diagnosis of haemophilia B (FIX (coagulation factor IX) activity\n             level below or equal to 2%) based on medical records or central laboratory results\n\n          -  Previously untreated or exposed to FIX containing products less than or equal to 3\n             exposure days (5 previous exposures to blood components is acceptable)\n\n        Exclusion Criteria:\n\n          -  Any history of FIX inhibitors (defined by medical records)\n\n          -  Known or suspected hypersensitivity to trial product or related products\n\n          -  Previous participation in this trial. Participation is defined as first dose\n             administered of trial product\n\n          -  Receipt of any investigational medicinal product within 30 days before screening\n\n          -  Congenital or acquired coagulation disorder other than haemophilia B\n\n          -  Any chronic disorder or severe disease which, in the opinion of the Investigator,\n             might jeopardise the patient's safety or compliance with the protocol\n\n          -  Patient's parent(s)/LAR(s) (legally acceptable representative) mental incapacity,\n             unwillingness to cooperate, or a language barrier precluding adequate understanding\n             and cooperation"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "6 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141074", 
            "org_study_id": "NN7999-3895", 
            "secondary_id": [
                "2012-004867-38", 
                "U1111-1135-9557"
            ]
        }, 
        "intervention": {
            "arm_group_label": "50 EDs (exposure days)", 
            "description": "For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.", 
            "intervention_name": "nonacog beta pegol", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Setif", 
                        "country": "Algeria", 
                        "zip": "19000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Klagenfurt", 
                        "country": "Austria", 
                        "zip": "9020"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "53127"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel-Hashomer", 
                        "country": "Israel", 
                        "zip": "52621"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10400"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Algeria", 
                "Austria", 
                "Germany", 
                "Israel", 
                "Spain", 
                "Taiwan", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Single-arm Multicentre Non-controlled Phase 3 a Trial Investigating Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Patients With Haemophilia B (FIX Activity Below or Equal to 2 Percent)", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Algeria: Ministry of Health", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Austria: Agency for Health and Food Safety", 
                "Brazil: National Health Surveillance Agency", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Canada: Health Canada", 
                "China: Ministry of Health", 
                "Denmark: Danish Medicines Agency", 
                "France: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Greece: National Organization of Medicines", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Malaysia: Ministry of Health", 
                "Mexico: National Institute of Public Health, Health Secretariat", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Poland: Ministry of Health", 
                "Portugal: National Pharmacy and Medicines Institute", 
                "Romania: National Medicines Agency", 
                "Serbia: Agency for Drugs and Medicinal Devices", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Spain: Spanish Agency of Medicines", 
                "Sweden: Medical Products Agency", 
                "Taiwan: Department of Health", 
                "Thailand: Ministry of Public Health", 
                "Turkey: Ministry of Health", 
                "Ukraine: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of inhibitory antibodies against coagulation factor IX (FIX)", 
                "safety_issue": "No", 
                "time_frame": "When the first 20 previously untreated patients (PUPs) have reached at least 50 exposure days (EDs) (Expected to reach between 12 - 24 months)"
            }, 
            {
                "measure": "Incidence of inhibitory antibodies against coagulation factor IX (FIX)", 
                "safety_issue": "No", 
                "time_frame": "When the first 40 PUPs have reached 100 EDs. (Expected to reach between 24 - 36 months)"
            }, 
            {
                "measure": "Incidence of inhibitory antibodies against coagulation factor IX (FIX)", 
                "safety_issue": "No", 
                "time_frame": "Expected to reach between 24 - 72 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141074"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number and frequency of adverse events", 
                "safety_issue": "No", 
                "time_frame": "When the first 20 PUPs have reached at least 50 EDs, when the first 40 PUPs have reached 100 EDs, and at end of trial (Expected to reach between 12 - 72 months)"
            }, 
            {
                "measure": "Number and frequency of serious adverse events", 
                "safety_issue": "No", 
                "time_frame": "When the first 20 PUPs have reached at least 50 EDs, when the first 40 PUPs have reached 100 EDs, and at end of trial (Expected to reach between 12 - 72 months)"
            }, 
            {
                "measure": "Number and frequency of Medical Events of Special Interest", 
                "safety_issue": "No", 
                "time_frame": "When the first 20 PUPs have reached at least 50 EDs, when the first 40 PUPs have reached 100 EDs, and at end of trial (Expected to reach between 12 - 72 months)"
            }, 
            {
                "measure": "Number of breakthrough bleeding episodes during prophylaxis (annualised bleeding rate) Haemostatic effect by 4-point haemostatic response scale (\"excellent\", \"good\", \"moderate\" and \"poor\")", 
                "safety_issue": "No", 
                "time_frame": "When the first 20 PUPs have reached at least 50 EDs, when the first 40 PUPs have reached 100 EDs, and at end of trial (Expected to reach between 12 - 72 months)"
            }, 
            {
                "measure": "Haemostatic effect by 4-point haemostatic response scale (\"excellent\", \"good\", \"moderate\" and \"poor\")", 
                "safety_issue": "No", 
                "time_frame": "When the first 20 PUPs have reached at least 50 EDs, when the first 40 PUPs have reached 100 EDs, and at end of trial (Expected to reach between 12 - 72 months)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}